#BreastCancerTreatment Archives

ESMO China Voice | Professor Xiaojia Wang: Aromatase Inhibitor Treatment for mBC Progression? Anlotinib Combined with Fulvestrant Offers New Hope

By Mourabit Halima 2024.01.21

Editor's Note: Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for over 70% of all breast cancers[1]. The use of CDK4/6 inhibitors has brought…

Professor Ying Fan: Evolution of HR+/HER2- Early Breast Cancer Adjuvant Treatment Strategies and Risk Stratification—Based on the Chinese Perspective

By Peng Longmei 2024.01.21

Editor's Note Breast cancer is the most common malignancy in women, with an increasing incidence in recent years. HR+/HER2- breast cancer accounts for approximately 70% of all breast cancer cases,…

ESMO 2023丨Professor Zhimin Shao: monarcE Study 5-Year Follow-Up Data Revealed, Sustained Benefit for Patients

By Mourabit Halima 2024.01.19

Editor's Note: The monarchE study is a randomized, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of abemaciclib combined with endocrine therapy versus endocrine therapy…